CG Oncology, Inc.
CGON
$63.67
-$0.79-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 409.21% | 3,774.42% | -- | -90.17% | 45,500.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 409.21% | 3,774.42% | -- | -90.17% | 45,500.00% |
| Cost of Revenue | 23.24% | 50.14% | 69.63% | 59.60% | 64.01% |
| Gross Profit | -16.56% | -41.96% | -70.66% | -64.35% | -61.23% |
| SG&A Expenses | 53.73% | 167.71% | 132.32% | 155.51% | 288.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.51% | 86.30% | 87.73% | 83.74% | 98.93% |
| Operating Income | -27.99% | -80.70% | -88.53% | -87.83% | -96.58% |
| Income Before Tax | -29.91% | -114.69% | -119.16% | -103.45% | -92.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.91% | -114.69% | -119.16% | -103.45% | -92.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.91% | -114.69% | -119.16% | -103.45% | -92.07% |
| EBIT | -27.99% | -80.70% | -88.53% | -87.83% | -96.58% |
| EBITDA | -25.76% | -79.36% | -87.98% | -87.76% | -96.63% |
| EPS Basic | -12.05% | -87.86% | -91.64% | -25.68% | 89.43% |
| Normalized Basic EPS | -12.06% | -87.89% | -91.60% | -25.66% | 85.64% |
| EPS Diluted | -12.05% | -87.86% | -91.64% | -25.68% | 89.43% |
| Normalized Diluted EPS | -12.06% | -87.89% | -91.60% | -25.66% | 85.64% |
| Average Basic Shares Outstanding | 15.94% | 14.28% | 14.37% | 61.88% | 1,237.29% |
| Average Diluted Shares Outstanding | 15.94% | 14.28% | 14.37% | 61.88% | 1,237.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |